Review
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 1, 2004; 10(21): 3088-3093
Published online Nov 1, 2004. doi: 10.3748/wjg.v10.i21.3088
CDH1 germline mutation in hereditary gastric carcinoma
Hai-Dan Wang, Jun Ren, Lian Zhang
Hai-Dan Wang, Center of Clinical Oncology and International Collaborative Group on Hereditary Gastric Carcinoma, Xijing Hospital, the Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China
Jun Ren, Lian Zhang, Peking University School of Oncology, Beijing 100036, China
Author contributions: All authors contributed equally to the work.
Supported by the Teaching and Research Award Program for Outstanding Young Teachers, Ministry of Education, P R China, No. TRAPOYT99-016
Correspondence to: Jun Ren, M.D.,Ph.D, Professor and Chairman, Department of Medical Oncology, Peking University School of Oncology, Beijing 100036, China. renjun@fmmu.edu.cn
Telephone: +86-10-88123125 Fax: +86-10-88122437
Received: November 17, 2003
Revised: January 8, 2004
Accepted: January 15, 2004
Published online: November 1, 2004
Abstract

This paper provides a bird’s-eye view both in preclinical and clinical aspects of E-cadherin germline gene (CDH1) in gastric cancer patients and their families. E-cadherin, a product of CDH1 gene, belonging to the functionally related trans-membrane glycoprotein family, is responsible for the Ca2+-dependent cell-cell adhesion mechanism and contributes to dissociation followed by acquisition of cell motility, which usually occurs in the first step of cancer invasion and metastasis. CDH1 gene germline mutation is common in many types of carcinoma, and occurs very frequent in hereditary gastric carcinoma (HGC) patients and their families. Recently, more and more researches support that E-cadherin plays an important role in the differentiation, growth and invasion of HGC. So it is of great value to clarify its mechanisms both for understanding HGC pathogenesis and for clinical therapy, especially in China, where there are a high risk population of gastric cancer and a high HGC incidence rate. In this paper, recent researches on CDH1 gene mutation, especially its role in tumor genesis and progress of HGC, are reviewed, and advances in evaluation of its mutation status for HGC diagnosis, therapy and prognosis, are also discussed briefly.

Keywords: $[Keywords]